Meridian Sees 20 to 30 Percent Growth in Fiscal 2012 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today provided guidance for its 2012 fiscal year, projecting net income to improve between 20 and 30 percent above projected fiscal 2011 income on the strength of its illumigene franchise.

For the year ending Sept. 30, 2012, the company expects EPS to fall between $.85 and $.89 on net sales of between $183 million and $192 million. The guidance excludes reorganization costs in 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.